by Cathy Yarborough, Science Writer
The predictive power of physiologically based pharmacokinetic (PBPK) modeling and simulation for first-in-human (FIH) studies has significantly improved during the past two decades.
As a result, pharmaceutical scientists now routinely employ these mechanistic models to predict a compound’s ADME properties for oral routes of administration. They have begun to use these models for non-oral routes as well, said Viera Lukacova, Ph.D., in her presentation, “Applicability of Existing Prediction Methods to Non-Oral Routes of Delivery.”